{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:10Z","timestamp":1792087330000,"version":"4.4.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,1,20]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (&gt; 90%) through month 12 (&gt; 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (&lt; 75 and \u2265 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (\n              <jats:italic>P<\/jats:italic>\n              = .0007\n              <jats:italic>v<\/jats:italic>\n              Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco.20.01370","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T21:04:34Z","timestamp":1608152674000},"page":"227-237","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":44,"title":["Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial"],"prefix":"10.1200","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct02252172","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Aurore","family":"Perrot","sequence":"first","affiliation":[{"name":"Hematology Department, Cancer University Institute Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Service des Maladies du Sang, H\u00f4pital Claude Huriez, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[{"name":"Vejle Hospital and University of Southern Denmark, Vejle, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute\/Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mayo Clinic Rochester, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital and University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Oxford University Hospital and NIHR BRC Blood Theme, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[{"name":"Hematology Department, Cancer University Institute Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Lyon-Sud Hematologie (HCL), Pierre\u2014Benite Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Hopital Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Fai","family":"Ho","sequence":"additional","affiliation":[{"name":"STAT-TU Inc, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Van Rampelbergh","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa M.","family":"Uhlar","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fastenau","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, BMT with Department of Pneumology, University Medical Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568915"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"e_1_3_9_13_2","volume-title":"DARZALEX\u00ae (daratumumab) injection, for intravenous use [packet insert]","year":"2019","unstructured":"DARZALEX\u00ae (daratumumab) injection, for intravenous use [packet insert]. Horsham, PA, Janssen Biotech, 2019"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1613886"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.352889.x"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.222667.x"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3564"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01665.x"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-70"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2644-6"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8035"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx002"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327481502200414"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2014.0089"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-00184-9"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2410-2"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0724"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.847933"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117077"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8042"}],"updated-by":[{"DOI":"10.1200\/jco-25-00558","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.01370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T20:02:33Z","timestamp":1743019353000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.01370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1,20]]}},"alternative-id":["10.1200\/JCO.20.01370"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.01370","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"2020-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}